Neoadjuvant therapy for melanoma: A U.S. Food and drug administration⇔melanoma research alliance public workshop

Kristen L. Mueller, Marc R. Theoret, Steven J. Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela M. DeMichele, Patrick M. Forde, Nageatte Ibrahim, Patricia Keegan, Tara C. Mitchell, Rebecca A. Moss, Caroline Robert, Rajeshwari Sridhara, Janis M. Taube, Michael T. Tetzlaff, Jennifer A. Wargo, Keith T. FlahertyMichael J. Kaplan, Suzanne L. Topalian, Ashley F. Ward, Marc S. Hurlbert

Research output: Contribution to journalReview articlepeer-review


Tremendous progress has been made in treating patients with metastatic melanoma over the past decade. In that timeframe, the FDA has approved 12 novel treatments for patients with advanced unresectable melanoma, comprising both kinase-targeted therapies and immune checkpoint inhibitors (ICI), and five treatments for adjuvant (postoperative) use in patients with high-risk resectable stage III melanoma. It is not known whether outcomes can be further improved by administering kinase inhibitors or ICI in the neoadjuvant (presurgical) setting in patients with high-risk resectable melanomas. Noting research community interest in exploring the neoadjuvant approach for treating melanoma and recognizing that early harmonization of methodologies may expedite the development of therapeutics in this space, the FDA and Melanoma Research Alliance convened a public workshop on November 6, 2019, in National Harbor, Maryland, to discuss key issues. The workshop consisted of 23 faculty and included more than 250 live participants. Topics discussed included opportunities for advancing novel endpoints for regulatory purposes as well as translational research, clinical trial design considerations, and strategies for optimizing patient selection while mitigating risk.

Original languageEnglish (US)
Pages (from-to)394-401
Number of pages8
JournalClinical Cancer Research
Issue number2
StatePublished - Jan 15 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Neoadjuvant therapy for melanoma: A U.S. Food and drug administration⇔melanoma research alliance public workshop'. Together they form a unique fingerprint.

Cite this